Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine vs Lidocaine for Carpal Tunnel Release
NCT05697276Completed
- Sponsor
- Hospital Italiano de Buenos Aires
- Start
- Sep 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of bupivacaine hydrochloride 0.75% injection in carpal tunnel syndrome (CTS) (2 arms), sponsored by Hospital Italiano de Buenos Aires. Primary endpoints: Postoperative Pain at 48 hours, Time until pain at 48 hours and 1 more. Started Sep 2022; status: completed.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
carpal tunnel syndrome (CTS)
Beyond the preview
Go deeper on NCT05697276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05697276.